arrow_back Back to App

Securing Drug Supply: Reducing Reliance on China for Pharmaceuticals.

This law aims to boost the security of the US drug supply chain by reducing dependence on China for finished medicines and active ingredients. It mandates the creation of a national strategy and prioritizes investments in pharmaceutical manufacturing both domestically and with allies. Citizens benefit from increased assurance that essential medications will remain reliably available.
Key points
The government must develop a strategy to decrease reliance on China for critical drug ingredients and finished products.
Financial support is prioritized for companies manufacturing drugs and ingredients outside of nonmarket economy countries (like China).
A confidential report must identify which drugs are more than 20% dependent on imports from China to pinpoint vulnerabilities.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2454
Sponsor: Sen. Lankford, James [R-OK]
Process start date: 2023-07-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Supply Chain Security Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2454.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-07-20.

What are the main provisions?

Key points include:

  • The government must develop a strategy to decrease reliance on China for critical drug ingredients and finished products.
  • Financial support is prioritized for companies manufacturing drugs and ingredients outside of nonmarket economy countries (like China).
  • A confidential report must identify which drugs are more than 20% dependent on imports from China to pinpoint vulnerabilities.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Lankford, James [R-OK].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Security